Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy

Dai, Jingyuan; Ashrafizadeh, Milad; Aref, Amir Reza; Sethi, Gautam; Ertas, Yavuz Nuri

doi:10.1016/j.drudis.2024.103981

Cited by 12 publications

(3 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the gene mutation sites in this study were reported in previous literatures [24][25][26][27][28][29][30][31][32][33][34][35], such as M133L, A159V, etc., which again verified the gene mutation characteristics and formation mechanism of OBI. This study found that there is a certain correlation between HBV S gene mutation and the pathogenesis of OBI, and if the S gene mutation is likely to lead to the omission of OBI.…”

Section: Discussionmentioning

confidence: 84%

Correlation analysis of latent hepatitis B virus infection gene mutation in unpaid blood donors

Yu,

Wang,

Liu

2024

Preprint

View full text Add to dashboard Cite

ObjectiveTo analyze the HBV S region gene mutation in serum samples of occult hepatitis B virus (HBV) infection (OB1), and to further analyze the mechanism of gene mutation and OBI.MethodsBlood samples from unpaid blood donors from January 2022 to December 2023 were collected and analyzed for serology, liver function indicators, viral load and gene mutation.ResultsA total of 90 OBI cases were detected, the detection rate was 0.051%, and the incidence of OBI was correlated with age. The sequence amplification of s region in the blood samples showed the presence of C type and B type genes, both of which occurred in the hydrophilic region.ConclusionThere is no abnormal liver function between OBI and hepatitis B population, and there is no difference in viral load between different serum modes. Mutations in the HBVS region are more likely to cause OBI, which provides a scientific basis for more sensitive HBV detection.

show abstract

Section: Discussionmentioning

confidence: 84%

Correlation analysis of latent hepatitis B virus infection gene mutation in unpaid blood donors

Yu,

Wang,

Liu

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Integration of cross-disciplinary technologies, such as nano-vehicle agents ( 322 ) combined with ferroptosis, may represent a more tailored approach to tumor treatment. However, several challenges must be addressed before clinical application.…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation

Cao,

Lu,

Beeraka

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Ferroptosis induces significant changes in mitochondrial morphology, including membrane condensation, volume reduction, cristae alteration, and outer membrane rupture, affecting mitochondrial function and cellular fate. Recent reports have described the intrinsic cellular iron metabolism and its intricate connection to ferroptosis, a significant kind of cell death characterized by iron dependence and oxidative stress regulation. Furthermore, updated molecular insights have elucidated the significance of mitochondria in ferroptosis and its implications in various cancers. In the context of cancer therapy, understanding the dual role of anastasis and ferroptosis in chemoresistance is crucial. Targeting the molecular pathways involved in anastasis may enhance the efficacy of ferroptosis inducers, providing a synergistic approach to overcome chemoresistance. Research into how DNA damage response (DDR) proteins, metabolic changes, and redox states interact during anastasis and ferroptosis can offer new insights into designing combinatorial therapeutic regimens against several cancers associated with stemness. These treatments could potentially inhibit anastasis while simultaneously inducing ferroptosis, thereby reducing the likelihood of cancer cells evading death and developing resistance to chemotherapy. The objective of this study is to explore the intricate interplay between anastasis, ferroptosis, EMT and chemoresistance, and immunotherapeutics to better understand their collective impact on cancer therapy outcomes. We searched public research databases including google scholar, PubMed, relemed, and the national library of medicine related to this topic. In this review, we discussed the interplay between the tricarboxylic acid cycle and glycolysis implicated in modulating ferroptosis, adding complexity to its regulatory mechanisms. Additionally, the regulatory role of reactive oxygen species (ROS) and the electron transport chain (ETC) in ferroptosis has garnered significant attention. Lipid metabolism, particularly involving GPX4 and System Xc- plays a significant role in both the progression of ferroptosis and cancer. There is a need to investigate the intricate interplay between anastasis, ferroptosis, and chemoresistance to better understand cancer therapy clinical outcomes. Integrating anastasis, and ferroptosis into strategies targeting chemoresistance and exploring its potential synergy with immunotherapy represent promising avenues for advancing chemoresistant cancer treatment. Understanding the intricate interplay among mitochondria, anastasis, ROS, and ferroptosis is vital in oncology, potentially revolutionizing personalized cancer treatment and drug development.

show abstract

“…It is estimated that there will be a 57.5% increase in 2040 compared to that in 2020, and the most common malignant tumors are solid tumors such as lung cancer, colorectal cancer, liver cancer, and gastric cancer [ 2 , 3 ]. Conventional chemotherapy remains the principal treatment modality for these malignancies [ 4 – 6 ]. However, the efficacy of traditional systemic chemotherapy is often compromised by low drug concentrations at tumor sites, resulting in suboptimal therapeutic outcomes.…”

Section: Introductionmentioning

confidence: 99%

Clinical research progress of callisperes® of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors

Wang,

Zhu,

Sheng

2024

Discov Onc

View full text Add to dashboard Cite

The incidence and mortality of cancer is ever-increasing, which poses a significant challengesto human health and a substantial economic burden to patients. At present, chemotherapy is still a primary treatment for various cancers. However, chemotherapy kills tumors but also induces the related side effects, whichadversely impacting patient quality of life and exacerbating suffering. Therefore, there is an urgent need for new and effective treatments that can control tumor growth while reducing the side effects for patients. Arterial chemoembolization has been attracted much attentionwhich attributed to the advantage of ability to embolize tumor vessels to block blood and nutrition supplies. Thus, to achieve local tumor control, it has become an effective means of local tumor control and has been widely used in clinical practice. Despite its efficacy, conventional arterial chemoembolization techniques, limited by embolization materials, have been associated with incomplete embolization and suboptimal drug delivery outcomes. Gradually, researchers have shifted their attention to a new type of embolic material called CalliSperes® drug-eluting embolic bead (DEB). DEB can not only load high doses of drugs, but also has strong sustained drug release ability and good biocompatibility. The integration of DEBs with traditional arterial chemoembolization (DEB-TACE) promises targeted vascular embolization, mitigated tumor ischemia and hypoxia, and direct intravascular chemotherapy delivery. It can prevent cancer cell differentiation and accelerate their death, meanwhile, directly injecting chemotherapy drugs into the target blood vessels reduced the blood concentration of the whole body, thus reduced the toxic and side effects of chemotherapy. Furthermore, DEB-TACE's sustained drug release capability elevates local drug concentrations at the tumor site, amplifying its antitumor efficacy. Therefore, DEB-TACE has become a hot spot in clinical research worldwide. This review introduces the pathogenesis of solid tumors, the background of research and biological characteristics of DEB, and the action mechanism of DEB-TACE, as well as its clinical research in various solid tumors and future prospects. This review aims to provide new ideas for the treatment of DEB-TACE in various solid tumors.

show abstract

Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy

Cited by 12 publications

References 137 publications

Correlation analysis of latent hepatitis B virus infection gene mutation in unpaid blood donors

Correlation analysis of latent hepatitis B virus infection gene mutation in unpaid blood donors

Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation

Clinical research progress of callisperes® of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors

Contact Info

Product

Resources

About